| [1] |
CaoW, ChenHD, YuYW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl),2021,134(7):783‑791. DOI:10.1097/CM9.000000000000 1474.
|
| [2] |
|
| [3] |
SongunI, PutterH, KranenbargEM, et al. Surgical treat-ment of gastric cancer: 15‑year follow‑up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol,2010,11(5):439‑449. DOI: 10.1016/S1470-2045(10)70070-X.
|
| [4] |
MaruyamaK, KaminishiM, HayashiK, et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry[J]. Gastric Cancer,2006,9(2):51‑66. DOI: 10.1007/s10120-006-0370-y.
|
| [5] |
KinoshitaT, MaruyamaK, SasakoM, et al. Treatment results of gastric cancer patients: Japanese experience[M/OL]. Nishi M, Ichikawa H, Nakajima T, et al., eds.//Gastric Cancer. Tokyo: Springer Japan,1993:319‑330[2022-01-17]. http://link.springer.com/ 10.1007/978-4-431-68328-5_23. DOI: 10.1007/978-4-431-68328-5_23.
|
| [6] |
WangFH, ZhangXT, LiYF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diag-nosis and treatment of gastric cancer,2021[J]. Cancer Commun (Lond),2021,41(8):747‑795. DOI:10.1002/cac2. 12193.
|
| [7] |
Japanese gastric cancer treatment guidelines2018(5th edition)[J]. Gastric Cancer,2021,24(1):1‑21. DOI: 10.1007/s10120-020-01042-y.
|
| [8] |
HuangC, LiuH, HuY, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five‑year outcomes from the CLASS‑01 randomized clinical trial[J]. JAMA Surg,2022,157(1):9‑17. DOI:10.1001/jamasurg.20 21.5104.
|
| [9] |
SasakoM, SakuramotoS, KataiH, et al. Five‑year out-comes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S‑1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer[J]. J Clin Oncol,2011,29(33):4387-4393. DOI: 10.1200/JCO.2011.36.5908.
|
| [10] |
KakejiY, YoshidaK, KoderaY, et al. Three‑year outcomes of a randomized phase Ⅲ trial comparing adjuvant che-motherapy with S‑1 plus docetaxel versus S‑1 alone in stage Ⅲ gastric cancer: JACCRO GC‑07[J]. Gastric Cancer,2022,25(1):188‑196. DOI: 10.1007/s10120-021-01224-2.
|
| [11] |
NohSH, ParkSR, YangHK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5‑year follow‑up of an open‑label, randomised phase 3 trial[J]. Lancet Oncol,2014,15(12):1389‑1396. DOI: 10.1016/S1470-2045(14)70473-5.
|
| [12] |
KimIH, ParkSS, LeeCM, et al. Efficacy of adjuvant S‑1 versus XELOX chemotherapy for patients with gastric can-cer after D2 lymph node dissection: a retrospective, multi-center observational study[J]. Ann Surg Oncol,2018,25(5):1176‑1183. DOI: 10.1245/s10434-018-6375-z.
|
| [13] |
ZhangX, LiangH, LiZ, et al. Perioperative or postopera-tive adjuvant oxaliplatin with S‑1 versus adjuvant oxali-platin with capecitabine in patients with locally advanced gastric or gastro‑oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open‑label, superiority and non‑inferiority, phase 3 randomised con-trolled trial[J]. Lancet Oncol,2021,22(8):1081‑1092. DOI: 10.1016/S1470-2045(21)00297-7.
|
| [14] |
PietrantonioF, MiceliR, RaimondiA, et al. Individual pati-ent data meta-analysis of the value of microsatellite insta-bility as a biomarker in gastric cancer[J]. J Clin Oncol,2019,37(35):3392-3400. DOI: 10.1200/JCO.19.01124.
|
| [15] |
SmalleySR, BenedettiJK, HallerDG, et al. Updated ana-lysis of SWOG‑directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J]. J Clin Oncol,2012,30(19):2327‑2333. DOI: 10.1200/JCO.2011.36.7136.
|
| [16] |
LeeJ, LimDH, KimS, et al. Phase Ⅲ trial comparing cape-citabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol,2012,30(3):268‑273. DOI: 10.1200/JCO.2011.39.1953.
|
| [17] |
ParkSH, LimDH, SohnTS, et al. A randomized phase Ⅲ trial comparing adjuvant single‑agent S1, S‑1 with oxali-platin, and postoperative chemoradiation with S‑1 and oxaliplatin in patients with node‑positive gastric cancer after D2 resection: the ARTIST 2 trial ☆[J]. Ann Oncol,2021,32(3):368‑374. DOI: 10.1016/j.annonc.2020.11.017.
|
| [18] |
CunninghamD, AllumWH, StenningSP, et al. Periopera-tive chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med,2006,355(1):11‑20. DOI: 10.1056/NEJMoa055531.
|
| [19] |
YchouM, BoigeV, PignonJP, et al. Perioperative chemo-therapy compared with surgery alone for resectable gastro-esophageal adenocarcinoma: an FNCLCC and FFCD multi-center phase Ⅲ trial[J]. J Clin Oncol,2011,29(13):1715-1721. DOI: 10.1200/JCO.2010.33.0597.
|
| [20] |
Al‑BatranSE, HomannN, PauligkC, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxalipla-tin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro‑oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet,2019, 393(10184):1948‑1957. DOI: 10.1016/S0140-6736(18)32557-1.
|
| [21] |
KangYK, YookJH, ParkYK, et al. PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S‑1 plus surgery and adjuvant S‑1 versus surgery and adjuvant S‑1 for resectable advanced gastric cancer[J]. J Clin Oncol,2021,39(26):2903‑2913. DOI: 10.1200/JCO.20.02914.
|
| [22] |
LiuX, XuP, QiuH, et al. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer[J]. Onco Targets Ther,2016,9:949‑958. DOI: 10.2147/OTT.S100979.
|
| [23] |
van HagenP, HulshofMC, van LanschotJJ, et al. Preopera-tive chemoradiotherapy for esophageal or junctional can-cer[J]. N Engl J Med,2012,366(22):2074‑2084. DOI:10.10 56/NEJMoa1112088.
|
| [24] |
LeongT, SmithersBM, HaustermansK, et al. TOPGEAR: a randomized, phase Ⅲ trial of perioperative ECF chemo-therapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an interna-tional, intergroup trial of the AGITG, TROG, EORTC and CCTG[J]. Ann Surg Oncol,2017,24(8):2252‑2258. DOI:10. 1245/s10434-017-5830-6.
|
| [25] |
BangYJ, Van CutsemE, FeyereislovaA, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‑positive advanced gastric or gastro‑oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet,2010,376(9742):687‑697. DOI: 10.1016/S0140-6736(10)61121-X.
|
| [26] |
RiveraF, Izquierdo‑ManuelM, García‑AlfonsoP, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with her2‑positive resectable gastric or gastro-oesophageal junction adenocarcinoma: neohx phase Ⅱ trial[J]. Eur J Cancer,2021,145:158‑167. DOI: 10.1016/j.ejca.2020.12.005.
|
| [27] |
HofheinzR, Hegewisch‑BeckerS, Thuss‑PatiencePC, et al. HER‑flot: trastuzumab in combination with flot as peri-operative treatment for patients with her2‑positive loca-lly advanced esophagogastric adenocarcinoma: a phase Ⅱ trial of the aio gastric cancer study group[J]. J Clin Oncol,2014,32(15_suppl): 4073. DOI: 10/gnvq74.
|
| [28] |
KataokaK, TokunagaM, MizusawaJ, et al. A randomized phase Ⅱ trial of systemic chemotherapy with and with-out trastuzumab followed by surgery in HER2‑positive advanced gastric or esophagogastric junction adenocarci-noma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study)[J]. Jpn J Clin Oncol,2015,45(11):1082‑1086. DOI: 10.1093/jjco/hyv134.
|
| [29] |
JanjigianYY, ShitaraK, MoehlerM, et al. First‑line nivolu-mab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro‑oesophageal junction, and oeso-phageal adenocarcinoma (CheckMate 649): a randomi-sed, open‑label, phase 3 trial[J]. Lancet,2021,398(10294):27‑40. DOI: 10.1016/S0140-6736(21)00797-2.
|
| [30] |
JanjigianYY, KawazoeA, YañezP, et al. The KEYNOTE‑811 trial of dual PD‑1 and HER2 blockade in HER2‑positive gastric cancer[J]. Nature,2021,600(7890):727‑730. DOI: 10.1038/s41586-021-04161-3.
|
| [31] |
TerashimaM, KimYW, YehTS, et al. ATTRACTION‑05 (ono-4538‑38/bms ca209844): a randomized, multicenter, double‑blind, placebo‑controlled phase 3 study of nivolu-mab (Nivo) in combination with adjuvant chemotherapy in pstage Ⅲ gastric and esophagogastric junction (G/EGJ) cancer[J]. Ann Oncol,2017,28(suppl 5):v266‑v267. DOI: 10/gm7fwx.
|
| [32] |
BangYJ, Van CutsemE, FuchsCS, et al. KEYNOTE‑585: Phase Ⅲ study of perioperative chemotherapy with or without pembrolizumab for gastric cancer[J]. Future Oncol,2019,15(9):943‑952. DOI: 10.2217/fon-2018-0581.
|
DownLoad: